Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment o

A 2026 systematic review and meta-analysis by Mounika Reddy, published on figshare, assesses the efficacy and safety of the novel antibiotic gepotidacin. The analysis includes three phase 3 clinical trials (EAGLE-1, EAGLE-2, EAGLE-3) involving 3,757 adults and adolescents with uncomplicated urogenital infections. It compares gepotidacin to standard-of-care antibiotics using pooled risk ratios for microbiological success, clinical cure, and serious adverse events.

Use Cases

• Comparing treatment efficacy for uncomplicated urinary tract infections based on microbiological success rates mentioned in the review
• Assessing drug safety profiles for urogenital gonorrhea based on serious adverse event data from the meta-analysis
• Evaluating a novel antibacterial agent's performance against resistant E. coli and N. gonorrhoeae strains as described
• Informing clinical guidelines for antibiotic use based on pooled risk ratios and GRADE evidence certainty

Strengths

• Analysis is based on three phase 3 randomized controlled trials totaling 3,757 participants
• Risk of bias was assessed using the Cochrane RoB2 tool and found to be low overall
• Results include specific pooled risk ratios with 95% confidence intervals for key outcomes

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is a 285.4 KB DOCX file, indicating a limited scope focused on the review document rather than raw trial data

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of three published phase 3 clinical trials (EAGLE-1, EAGLE-2, EAGLE-3).

Time Range

Publication date 2026; underlying trial dates are not specified.

Freshness

Last updated 2026-05-06 08:46:07; freshness should be verified

Geography

null